

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

MedGenome makes majority investment in Mumbai-based Medcare Diagnostics

02 March 2026 | News

Medcare's promoters will continue to lead operations and drive its next phase of growth in collaboration with MedGenome



Bengaluru-based MedGenome has announced a majority investment in Mumbai-headquartered Medcare Management Services, a leading radiology and nuclear medicine provider specialising in PET-CT and advanced molecular imaging services.

Medcare Management Services offers advanced imaging services, including PET-CT, CT, Mammography, Nuclear Medicine Scans, and theragnostic facilities. Over the past decade, through partnerships with over 50 hospitals and leading physicians across the city, Medcare has built credibility for its clinical excellence, accessibility, and patient care in the region.

Nuclear medicine plays a major role in the areas of Oncology, Cardiology, and Neurology for diagnosis as well as in treatment planning. PET-CT Imaging, complemented with genetic tests, enables early cancer detection and has a significant impact on the course of treatment and monitoring, delivering enhanced patient outcomes.

Dr Atul Marwah, Founder, Medcare, added, "As a part of MedGenome, Medcare can unlock significant growth opportunities, enabling us to offer integrated imaging, pathology, and genomics solutions, which are especially critical in oncology and the management of complex diseases."

Commenting on this alliance, Dr Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, and Chairman of the Board of MedGenome, said, "MedGenome's investment in Medcare marks an important step in strengthening its vision of building an integrated diagnostics ecosystem for India. By bringing together Medcare's imaging and pathology expertise with MedGenome's leadership in multi-omics, this partnership expands access to earlier and more precise diagnostics for patients. As an investor, Novo Holdings is pleased to support this next phase of growth as the company continues advancing high-quality, science-led healthcare."

The collaboration fortifies MedGenome's strategy of evolving into a truly integrated diagnostics player, with a focus on multi-omics. By strengthening its capabilities across radiology, pathology, and genomics, the company is poised to deliver more comprehensive, technology-driven, and patient-centric solutions, expand its reach and footprint, and improve the accessibility of advanced precision diagnostics across India.